AstraZeneca Expands Lymphoma Pipeline With TeneoTwo Acquisition

Enters Crowded Bispecific Field

 
• By Andrew McConaghie

AstraZeneca has bought TeneoTwo and its bispecific asset TNB-486 to enlarge its hemato-oncology pipeline but the UK major is still a long way off being a key player in the field.

AZ building
AstraZeneca's Calquence is a major success in non-Hodgkin's lymphoma, but bispecifics are expected to play a major part in future therapy. • Source: Shutterstock

More from Business

More from Scrip